Friday, August 07, 2020
Caprion-HistoGeneX and Viroclinics-DDL announced a new strategic partnership to expand their global capabilities that address emerging needs for therapeutic and prophylactic solutions aimed at infectious diseases, including COVID-19. This association brings together the leadership of two leading contract research organizations that serve the pharmaceutical and biotechnology community with specialized trials and technologies relevant to preclinical and clinical studies to develop vaccines and other therapies for infectious diseases.
Combining their respective expertise, the two companies offer a full range of specialized services to support vaccine and antiviral studies alongside a broad global presence, including sites in the Netherlands, Canada, the United States, Belgium, the United Kingdom, Australia. and China .
" We are delighted to partner with Caprion-HistoGeneX and combine our unique strength to enable our companies to deliver world-class contract research services for our clients developing innovative modalities to fight infectious diseases ," explained Davide Molho DVM, new CEO. by Viroclinics-DDL.
The partnership will enable an integrated service experience for clients around the world, with a broad service offering covering all phases of vaccine and anti-viral development, ranging from preclinical and in-vitro research models to the deployment of developed and customized functional assays and ready-to-use type for the control of the efficacy of the vaccine. In addition to enhancing a wide selection of specialized platforms, such as viral neutralization, flow cytometry, ELISpot, and immunoassays, the partnership will provide access to an expanded global network of clinical sample processing facilities in North America, South America, Europe, Africa and Asia., together with the operational and logistical services that include sample management and sample kits.
"With our complementary competencies, we have been able to fulfill the R&D and clinical outsourcing needs for the market. Following the current COVID-19 pandemic, we believe this joint initiative will take vaccine and antiviral testing to the next level. " said Martin LeBlanc , CEO of Caprion-HistoGeneX.
